Trial Outcomes & Findings for Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design (NCT NCT00978341)

NCT ID: NCT00978341

Last Updated: 2021-01-25

Results Overview

Present pain intensity score: 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

15 participants

Primary outcome timeframe

Day 1: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours (post-dose); Day 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours (post-dose)

Results posted on

2021-01-25

Participant Flow

Subjects were enrolled at 4 study centers and participated in the study between 13 February 2007 and 01 October 2008.

Subjects completed a 1-2 week screening period to determine eligibility criteria prior to enrollment. Of 24 subjects screened, 15 subjects were enrolled into the study and randomized.

Participant milestones

Participant milestones
Measure
Pregabalin First Then Placebo
First Intervention Pregabalin Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning. Second Intervention Placebo Days 1-7: twice a day (BID); Day 8: 1 dose in the morning.
Placebo First Then Pregabalin
First Intervention Placebo Days 1-7: twice a day (BID); Day 8: 1 dose in the morning. Second Intervention Pregabalin: Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
First Intervention
STARTED
8
7
First Intervention
COMPLETED
8
7
First Intervention
NOT COMPLETED
0
0
Washout Period of 2 Weeks
STARTED
8
7
Washout Period of 2 Weeks
COMPLETED
7
7
Washout Period of 2 Weeks
NOT COMPLETED
1
0
Second Intervention
STARTED
7
7
Second Intervention
COMPLETED
7
7
Second Intervention
NOT COMPLETED
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Pregabalin First Then Placebo
First Intervention Pregabalin Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning. Second Intervention Placebo Days 1-7: twice a day (BID); Day 8: 1 dose in the morning.
Placebo First Then Pregabalin
First Intervention Placebo Days 1-7: twice a day (BID); Day 8: 1 dose in the morning. Second Intervention Pregabalin: Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Washout Period of 2 Weeks
Adverse Event
1
0

Baseline Characteristics

Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Subjects
n=15 Participants
Pregabalin: Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning; and Placebo: Days 1-7: twice a day (BID); Day 8: 1 dose in the morning.
Age, Customized
18-44 years
5 participants
n=99 Participants
Age, Customized
45-64 years
7 participants
n=99 Participants
Age, Customized
>= 65 years
3 participants
n=99 Participants
Sex/Gender, Customized
Female
2 gender
n=99 Participants
Sex/Gender, Customized
Male
13 gender
n=99 Participants

PRIMARY outcome

Timeframe: Day 1: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours (post-dose); Day 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours (post-dose)

Population: Full analysis set (FAS): those subjects who completed both periods of the study. Combined results for At-level and Below-level neuropathic pain; At-level: located within 2 dermatomes above or below the level of spinal cord injury; Below-level: located at least 3 dermatomes below the level of spinal cord injury.

Present pain intensity score: 0-10 numeric rating scale (NRS), 0 (no pain) to 10 (worst possible pain).

Outcome measures

Outcome measures
Measure
Pregabalin
n=15 Participants
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 Participants
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning
Present Pain Intensity Score
Day 8: 1 hour post-dose (n=13, 14)
4.0 scores on scale
Standard Deviation 2.71
4.9 scores on scale
Standard Deviation 2.60
Present Pain Intensity Score
Day 8: 2 hours post-dose (n=13, 14)
4.6 scores on scale
Standard Deviation 2.50
4.6 scores on scale
Standard Deviation 2.38
Present Pain Intensity Score
Day 1: pre-dose (n=15, 14)
5.3 scores on scale
Standard Deviation 2.76
4.9 scores on scale
Standard Deviation 2.91
Present Pain Intensity Score
Day 1: 0.5 hours post-dose (n=15, 14)
5.1 scores on scale
Standard Deviation 2.46
4.6 scores on scale
Standard Deviation 3.03
Present Pain Intensity Score
Day 1: 1 hours post-dose (n=15, 14)
4.6 scores on scale
Standard Deviation 2.82
4.7 scores on scale
Standard Deviation 2.55
Present Pain Intensity Score
Day 1: 2 hours post-dose (n=15, 14)
4.3 scores on scale
Standard Deviation 2.64
4.7 scores on scale
Standard Deviation 2.64
Present Pain Intensity Score
Day 1: 3 hours post-dose (n=15, 14)
4.3 scores on scale
Standard Deviation 2.82
4.7 scores on scale
Standard Deviation 2.73
Present Pain Intensity Score
Day 1: 4 hours post-dose (n=15, 14)
4.1 scores on scale
Standard Deviation 2.79
4.6 scores on scale
Standard Deviation 2.98
Present Pain Intensity Score
Day 1: 5 hours post-dose (n=15, 14)
3.9 scores on scale
Standard Deviation 3.01
4.9 scores on scale
Standard Deviation 3.02
Present Pain Intensity Score
Day 1: 6 hours post-dose (n=15, 14)
3.9 scores on scale
Standard Deviation 2.89
5.1 scores on scale
Standard Deviation 2.91
Present Pain Intensity Score
Day 1: 8 hours post-dose (n=15, 14)
4.3 scores on scale
Standard Deviation 2.91
5.1 scores on scale
Standard Deviation 2.57
Present Pain Intensity Score
Day 1: 10 hours post-dose (n=14, 14)
4.1 scores on scale
Standard Deviation 3.03
5.3 scores on scale
Standard Deviation 2.81
Present Pain Intensity Score
Day 1: 12 hours post-dose (n=14, 14)
4.1 scores on scale
Standard Deviation 3.17
5.4 scores on scale
Standard Deviation 2.68
Present Pain Intensity Score
Day 8: pre-dose (n=13, 14)
4.7 scores on scale
Standard Deviation 2.53
5.4 scores on scale
Standard Deviation 2.62
Present Pain Intensity Score
Day 8: 0.5 hours post-dose (n=13, 14)
4.5 scores on scale
Standard Deviation 2.33
5.0 scores on scale
Standard Deviation 2.57
Present Pain Intensity Score
Day 8: 3 hours post-dose (n=15, 14)
4.9 scores on scale
Standard Deviation 2.22
4.7 scores on scale
Standard Deviation 2.52
Present Pain Intensity Score
Day 8: 4 hours post-dose (n=15, 14)
4.9 scores on scale
Standard Deviation 2.28
4.9 scores on scale
Standard Deviation 2.53
Present Pain Intensity Score
Day 8: 5 hours post-dose (n=15, 14)
4.8 scores on scale
Standard Deviation 2.40
4.9 scores on scale
Standard Deviation 2.63
Present Pain Intensity Score
Day 8: 6 hours post-dose (n=15, 14)
4.4 scores on scale
Standard Deviation 2.38
5.2 scores on scale
Standard Deviation 2.72
Present Pain Intensity Score
Day 8: 8 hours post-dose (n=15, 13)
4.7 scores on scale
Standard Deviation 2.63
5.3 scores on scale
Standard Deviation 2.90
Present Pain Intensity Score
Day 8: 10 hours post-dose (n=15, 13)
4.9 scores on scale
Standard Deviation 2.37
5.2 scores on scale
Standard Deviation 2.85
Present Pain Intensity Score
Day 8: 12 hours post-dose (n=15, 13)
4.7 scores on scale
Standard Deviation 2.16
5.2 scores on scale
Standard Deviation 2.65
Present Pain Intensity Score
Day 8: 24 hours post-dose (n=15, 14)
5.0 scores on scale
Standard Deviation 2.36
5.4 scores on scale
Standard Deviation 2.71
Present Pain Intensity Score
Day 8: 36 hours post-dose (n=15, 13)
6.1 scores on scale
Standard Deviation 2.74
5.7 scores on scale
Standard Deviation 2.56
Present Pain Intensity Score
Day 8: 48 hours post-dose (n=15, 14)
6.1 scores on scale
Standard Deviation 2.31
5.8 scores on scale
Standard Deviation 2.81

SECONDARY outcome

Timeframe: Predose: Daily from 7 days before Visit 2 (start of Intervention 1) until the morning of Visit 5 (end of Intervention 2)

Population: FAS; Combined results for At-level and Below-level of spinal cord injury.

Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).

Outcome measures

Outcome measures
Measure
Pregabalin
n=15 Participants
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 Participants
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning
Daily Pain Score
Day 5 (n= 15, 14)
4.5 scores on scale
Standard Deviation 2.67
5.1 scores on scale
Standard Deviation 2.37
Daily Pain Score
Day 1 (n=15, 13)
6.2 scores on scale
Standard Deviation 1.78
6.3 scores on scale
Standard Deviation 2.06
Daily Pain Score
Day 2 (n=15, 14)
4.4 scores on scale
Standard Deviation 2.67
5.4 scores on scale
Standard Deviation 2.47
Daily Pain Score
Day 3 (n=15, 14)
4.1 scores on scale
Standard Deviation 2.49
5.1 scores on scale
Standard Deviation 2.35
Daily Pain Score
Day 4 (n=15, 14)
4.2 scores on scale
Standard Deviation 2.51
5.0 scores on scale
Standard Deviation 2.35
Daily Pain Score
Day 6 (n=15, 14)
3.7 scores on scale
Standard Deviation 2.60
4.9 scores on scale
Standard Deviation 2.30
Daily Pain Score
Day 7 (n=15, 14)
4.0 scores on scale
Standard Deviation 2.70
4.9 scores on scale
Standard Deviation 2.54
Daily Pain Score
Day 8 (n=14, 14)
4.0 scores on scale
Standard Deviation 2.35
5.6 scores on scale
Standard Deviation 2.47

SECONDARY outcome

Timeframe: Screening, Days 1 & 8: 0 (pre-dose) & 4 hours post-dose,

Population: FAS; Combined results for At-level and Below-level of spinal cord injury.

Area of dynamic allodynia was assessed using a brush (SENSElab Brush 05; velocity approximately 20 millimeters per second \[mm/s\]) by stimulating along a pattern of 8 radial spokes. Stimulation was started from the non-painful perimetry. Subjects were asked to report change in sensation from non-painful to painful and the spot was marked onto the skin. The area of dynamic allodynia was determined from these 8 distances by calculating the area of an octagon (in centimeter squared \[cm2\]).

Outcome measures

Outcome measures
Measure
Pregabalin
n=15 Participants
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 Participants
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning
Dynamic Allodynia Area
Day 1: pre-dose (n=14, 14)
95.8 cm2
Standard Deviation 108.1
81.6 cm2
Standard Deviation 111.2
Dynamic Allodynia Area
Day 1: 4 hours post-dose (n=15, 13)
63.0 cm2
Standard Deviation 78.54
50.9 cm2
Standard Deviation 78.64
Dynamic Allodynia Area
Day 8: pre-dose (n=12, 14)
48.4 cm2
Standard Deviation 92.07
68.4 cm2
Standard Deviation 83.53
Dynamic Allodynia Area
Day 8: 4 hours post-dose (n=15, 13)
50.5 cm2
Standard Deviation 83.72
68.0 cm2
Standard Deviation 91.41

SECONDARY outcome

Timeframe: Screening, Days 1 & 8: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, and 6 hours post-dose

Population: FAS; Combined results for At-level and Below-level of spinal cord injury.

Five strokes (each approx. 6 centimeters \[cm\] long) were applied with a standardized brush (SENSELab Brush 05) across the painful site (and a control site) at a constant velocity (20 millimeters per second \[mm/sec\]). Pain in response to brush stimulation of the allodynic area was recorded using an 11-point numeric rating scale from 0 (no pain) to 10 (worst possible pain). Patients were asked to give a pain rating after each brush stroke. A painful sensation was considered as representing brush allodynia.

Outcome measures

Outcome measures
Measure
Pregabalin
n=15 Participants
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 Participants
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning
Dynamic Allodynia Pain Score
Day 8: pre-dose (n=11, 12)
1.9 scores on scale
Standard Deviation 2.93
2.0 scores on scale
Standard Deviation 2.97
Dynamic Allodynia Pain Score
Day 1: 1 hour post-dose (n=10, 8)
2.3 scores on scale
Standard Deviation 2.83
1.8 scores on scale
Standard Deviation 3.15
Dynamic Allodynia Pain Score
Day 1: 2 hours post-dose (n=10, 8)
2.5 scores on scale
Standard Deviation 3.09
1.7 scores on scale
Standard Deviation 2.67
Dynamic Allodynia Pain Score
Day 1: 3 hours post-dose (n=10, 8)
2.3 scores on scale
Standard Deviation 2.94
2.3 scores on scale
Standard Deviation 2.98
Dynamic Allodynia Pain Score
Day 1: 4 hours post-dose (n=15, 13)
1.5 scores on scale
Standard Deviation 2.63
1.2 scores on scale
Standard Deviation 2.28
Dynamic Allodynia Pain Score
Day 1: 5 hours post-dose (n=10, 8)
2.2 scores on scale
Standard Deviation 2.95
1.9 scores on scale
Standard Deviation 2.70
Dynamic Allodynia Pain Score
Day 1: 6 hours post-dose (n=10, 8)
2.1 scores on scale
Standard Deviation 2.80
1.9 scores on scale
Standard Deviation 2.75
Dynamic Allodynia Pain Score
Day 8: 0.5 hours post-dose (n=7, 8)
1.7 scores on scale
Standard Deviation 2.74
1.7 scores on scale
Standard Deviation 2.66
Dynamic Allodynia Pain Score
Day 8: 1 hour post-dose (n=7, 8)
1.6 scores on scale
Standard Deviation 2.66
1.4 scores on scale
Standard Deviation 2.58
Dynamic Allodynia Pain Score
Day 8: 2 hours post-dose (n=7, 8)
1.9 scores on scale
Standard Deviation 2.93
1.5 scores on scale
Standard Deviation 2.43
Dynamic Allodynia Pain Score
Day 8: 3 hours post-dose (n=9, 8)
1.7 scores on scale
Standard Deviation 2.45
1.6 scores on scale
Standard Deviation 2.51
Dynamic Allodynia Pain Score
Day 8: 4 hours post-dose (n=14, 13)
1.0 scores on scale
Standard Deviation 1.99
0.9 scores on scale
Standard Deviation 1.99
Dynamic Allodynia Pain Score
Day 8: 5 hours post-dose (n=9, 8)
1.9 scores on scale
Standard Deviation 2.83
1.5 scores on scale
Standard Deviation 2.40
Dynamic Allodynia Pain Score
Day 8: 6 hours post-dose (n=9, 8)
1.9 scores on scale
Standard Deviation 3.05
1.5 scores on scale
Standard Deviation 2.57
Dynamic Allodynia Pain Score
Day 1: pre-dose (n=14, 13)
2.2 scores on scale
Standard Deviation 2.99
2.1 scores on scale
Standard Deviation 3.33
Dynamic Allodynia Pain Score
Day 1: 0.5 hours post-dose (n=10, 8)
2.8 scores on scale
Standard Deviation 3.14
1.9 scores on scale
Standard Deviation 3.35

SECONDARY outcome

Timeframe: Screening, Days 1 & 8: 0 (pre-dose) and 4 hours post-dose

Population: FAS; combined results for At-level and Below-level spinal cord injury.

Area of punctate allodynia was determined using a von Frey filament (OptiHair2). Stimulation was started from the non-painful perimetry and repeated along a pattern of 8 radial spokes. With a movement along each spoke at steps of 5 millimeters (mm), the subjects reported sensation changes from non-painful to painful and the spot was marked on the skin. The area of punctate allodynia was determined from these 8 distances by calculating the area of an octagon (in square centimeter(s)\[cm2\]).

Outcome measures

Outcome measures
Measure
Pregabalin
n=15 Participants
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 Participants
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning
Punctate Allodynia Area
Day 1: pre-dose (n=15, 14)
75.6 cm2
Standard Deviation 113.3
65.1 cm2
Standard Deviation 104.8
Punctate Allodynia Area
Day 1: 4 hours post-dose (n=15, 13)
68.7 cm2
Standard Deviation 112.6
54.1 cm2
Standard Deviation 91.21
Punctate Allodynia Area
Day 8: pre-dose (n=13, 14)
53.1 cm2
Standard Deviation 102.2
45.9 cm2
Standard Deviation 74.32
Punctate Allodynia Area
Day 8: 4 hours post-dose (n=15, 13)
70.8 cm2
Standard Deviation 106.3
46.7 cm2
Standard Deviation 80.73

SECONDARY outcome

Timeframe: Screening, Days 1 & 8: 0 (pre-dose), & 2, 4, and 6 hours post-dose

Population: FAS; combined results for At-level and Below-level of spinal cord injury.

Mechanical pain sensitivity stimulus response function was assessed at the control and painful sites using calibrated von Frey monofilaments and the SENSElab brush. Seven different von Frey monofilaments (8 -512 milliNewtons \[mN\], force increases by a factor of two from filament to filament) and the brush were applied in a predetermined pseudo-random order. Pain rating for each stimulus: 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain).

Outcome measures

Outcome measures
Measure
Pregabalin
n=14 Participants
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 Participants
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning
Mechanical Pain Sensitivity Stimulus-Response Function
Day 1: 2 hours post-dose (n=14, 14)
0.7 scores on scale
Standard Deviation 0.58
0.8 scores on scale
Standard Deviation 0.65
Mechanical Pain Sensitivity Stimulus-Response Function
Day 1: 6 hours post-dose (n=14, 14)
0.8 scores on scale
Standard Deviation 0.61
0.9 scores on scale
Standard Deviation 0.68
Mechanical Pain Sensitivity Stimulus-Response Function
Day 1: pre-dose (n=14, 14)
0.8 scores on scale
Standard Deviation 0.78
0.9 scores on scale
Standard Deviation 0.73
Mechanical Pain Sensitivity Stimulus-Response Function
Day 1: 4 hours post-dose (n=14, 14)
0.7 scores on scale
Standard Deviation 0.64
0.8 scores on scale
Standard Deviation 0.65
Mechanical Pain Sensitivity Stimulus-Response Function
Day 8: pre-dose (n=13, 14)
0.7 scores on scale
Standard Deviation 0.61
0.8 scores on scale
Standard Deviation 0.64
Mechanical Pain Sensitivity Stimulus-Response Function
Day 8: 2 hours post-dose (=13, 14)
0.7 scores on scale
Standard Deviation 0.50
0.8 scores on scale
Standard Deviation 0.66
Mechanical Pain Sensitivity Stimulus-Response Function
Day 8: 4 hours post-dose (n=15, 13)
0.7 scores on scale
Standard Deviation 0.65
0.7 scores on scale
Standard Deviation 0.62
Mechanical Pain Sensitivity Stimulus-Response Function
Day 8: 6 hours post-dose (n=15, 13)
0.8 scores on scale
Standard Deviation 0.67
0.7 scores on scale
Standard Deviation 0.59

SECONDARY outcome

Timeframe: Prior to morning dosing on Day 1 and prior to discharge on Day 8 for each period.

Population: FAS; Combined results for At-level and Below-level of spinal cord injury.

NPSI: subject rated questionnaire to evaluate 5 dimensions of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia). Includes 10 descriptors ranging from 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each relevant dimension. Total score is calculated as the sum of scores of the 10 descriptors, range: 0-100. Higher score indicates greater intensity of pain.

Outcome measures

Outcome measures
Measure
Pregabalin
n=15 Participants
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 Participants
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning
Neuropathic Pain Symptom Inventory (NPSI)
Category 4: Day 8 (n=12, 11)
2.7 scores on scale
Interval 0.8 to 4.7
0.0 scores on scale
Interval 0.0 to 4.0
Neuropathic Pain Symptom Inventory (NPSI)
Category 1 Day 1 (n=15, 14)
6.0 scores on scale
Interval 3.0 to 7.0
6.0 scores on scale
Interval 0.0 to 7.0
Neuropathic Pain Symptom Inventory (NPSI)
Category 1: Day 8 (n=12, 11)
5.5 scores on scale
Interval 1.5 to 7.0
6.0 scores on scale
Interval 0.0 to 7.0
Neuropathic Pain Symptom Inventory (NPSI)
Category 2: Day 1 (n=15, 14)
3.0 scores on scale
Interval 1.0 to 5.0
2.5 scores on scale
Interval 1.0 to 4.0
Neuropathic Pain Symptom Inventory (NPSI)
Category 2: Day 8 (n=12, 11)
2.5 scores on scale
Interval 1.5 to 3.3
3.0 scores on scale
Interval 2.0 to 4.5
Neuropathic Pain Symptom Inventory (NPSI)
Category 3: Day 1 (n=15, 14)
1.5 scores on scale
Interval 0.0 to 5.0
3.3 scores on scale
Interval 1.0 to 5.0
Neuropathic Pain Symptom Inventory (NPSI)
Category 3: Day 8 (n=12, 11)
1.8 scores on scale
Interval 0.0 to 3.5
2.0 scores on scale
Interval 0.0 to 5.0
Neuropathic Pain Symptom Inventory (NPSI)
Category 4: Day 1 (n=15, 14)
1.7 scores on scale
Interval 0.0 to 6.0
0.3 scores on scale
Interval 0.0 to 3.3
Neuropathic Pain Symptom Inventory (NPSI)
Category 5: Day 1 (n=15, 14)
5.0 scores on scale
Interval 0.0 to 7.0
5.0 scores on scale
Interval 1.5 to 7.0
Neuropathic Pain Symptom Inventory (NPSI)
Category 5: Day 8 (n=12, 11)
3.5 scores on scale
Interval 1.5 to 5.5
5.0 scores on scale
Interval 2.0 to 6.0
Neuropathic Pain Symptom Inventory (NPSI)
Total: Day 1 (n=15, 14)
32 scores on scale
Interval 14.0 to 48.0
27 scores on scale
Interval 21.0 to 42.0
Neuropathic Pain Symptom Inventory (NPSI)
Total: Day 8 (n=12, 11)
22 scores on scale
Interval 18.5 to 51.5
24 scores on scale
Interval 20.0 to 46.0

SECONDARY outcome

Timeframe: Day 1: 0 (pre-dose), 0.5, 1, 2, and 6 hours post-dose; Day 8: 0 (pre-dose), 1, 4, & 6 hours post-dose

Pharmacokinetic (PK) results are not presented in this report due to early termination of the trial. Pregabalin PK was not measured as there was incomplete data to conduct pharmacokinetic/pharmacodynamic analyses.

Outcome measures

Outcome data not reported

Adverse Events

Pregabalin

Serious events: 0 serious events
Other events: 12 other events
Deaths: 0 deaths

Placebo

Serious events: 1 serious events
Other events: 9 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Pregabalin
n=15 participants at risk
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 participants at risk
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning.
Infections and infestations
Urinary tract infection
0.00%
0/15
7.1%
1/14

Other adverse events

Other adverse events
Measure
Pregabalin
n=15 participants at risk
Days 1-7: 150 mg twice a day (BID); Day 8: 150 mg in the morning.
Placebo
n=14 participants at risk
Days 1-7: twice a day (BID); Day 8: 1 dose in the morning.
Injury, poisoning and procedural complications
Fall
6.7%
1/15
7.1%
1/14
Investigations
Alanine aminotransferase increased
6.7%
1/15
0.00%
0/14
Investigations
Aspartate aminotransferase increased
6.7%
1/15
0.00%
0/14
Investigations
Urine analysis abnormal
0.00%
0/15
7.1%
1/14
Metabolism and nutrition disorders
Hypocalcaemia
0.00%
0/15
7.1%
1/14
Musculoskeletal and connective tissue disorders
Muscle spasms
0.00%
0/15
7.1%
1/14
Musculoskeletal and connective tissue disorders
Neck pain
0.00%
0/15
7.1%
1/14
Nervous system disorders
Dizziness
26.7%
4/15
7.1%
1/14
Nervous system disorders
Dizziness postural
6.7%
1/15
0.00%
0/14
Nervous system disorders
Headache
20.0%
3/15
14.3%
2/14
Cardiac disorders
Palpitations
6.7%
1/15
0.00%
0/14
Congenital, familial and genetic disorders
Dermoid cyst
6.7%
1/15
7.1%
1/14
Eye disorders
Eye pain
0.00%
0/15
7.1%
1/14
Gastrointestinal disorders
Diarrhoea
6.7%
1/15
0.00%
0/14
Gastrointestinal disorders
Dry mouth
13.3%
2/15
7.1%
1/14
Gastrointestinal disorders
Dyspepsia
6.7%
1/15
0.00%
0/14
Gastrointestinal disorders
Vomiting
6.7%
1/15
0.00%
0/14
General disorders
Catheter related complication
0.00%
0/15
7.1%
1/14
General disorders
Chest pain
6.7%
1/15
0.00%
0/14
General disorders
Chills
6.7%
1/15
0.00%
0/14
General disorders
Fatigue
6.7%
1/15
0.00%
0/14
General disorders
Feeling drunk
13.3%
2/15
0.00%
0/14
General disorders
Feeling hot
6.7%
1/15
7.1%
1/14
General disorders
Oedema peripheral
6.7%
1/15
0.00%
0/14
General disorders
Pyrexia
13.3%
2/15
0.00%
0/14
Infections and infestations
Oral candidiasis
0.00%
0/15
7.1%
1/14
Infections and infestations
Urinary tract infection
26.7%
4/15
14.3%
2/14
Nervous system disorders
Hypoaesthesia
6.7%
1/15
0.00%
0/14
Nervous system disorders
Lethargy
6.7%
1/15
7.1%
1/14
Nervous system disorders
Muscle spasticity
6.7%
1/15
0.00%
0/14
Nervous system disorders
Neuralgia
13.3%
2/15
7.1%
1/14
Nervous system disorders
Somnolence
33.3%
5/15
14.3%
2/14
Nervous system disorders
Tension headache
6.7%
1/15
0.00%
0/14
Psychiatric disorders
Euphoric mood
6.7%
1/15
0.00%
0/14
Renal and urinary disorders
Stress urinary incontinence
6.7%
1/15
0.00%
0/14
Skin and subcutaneous tissue disorders
Dermatitis
0.00%
0/15
7.1%
1/14

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: OTHER